These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39207758)

  • 1. Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time.
    Xuan Z; Walley AY; Yan S; Chatterjee A; Green TG; Pollini RA
    JAMA Netw Open; 2024 Aug; 7(8):e2427236. PubMed ID: 39207758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Implementation of Postoverdose Outreach Programs With Subsequent Opioid Overdose Deaths Among Massachusetts Municipalities.
    Xuan Z; Yan S; Formica SW; Green TC; Beletsky L; Rosenbloom D; Bagley SM; Kimmel SD; Carroll JJ; Lambert AM; Walley AY
    JAMA Psychiatry; 2023 May; 80(5):468-477. PubMed ID: 36920385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
    Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the naloxone standing order on trends in opioid fatal overdose: an ecological analysis.
    Taylor M; Pradhan A; Ogando YM; Shaya F
    Am J Drug Alcohol Abuse; 2022 May; 48(3):338-346. PubMed ID: 35467459
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
    Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts.
    Chatterjee A; Yan S; Xuan Z; Waye KM; Lambert AM; Green TC; Stopka TJ; Pollini RA; Morgan JR; Walley AY
    Drug Alcohol Depend; 2022 Jan; 230():109190. PubMed ID: 34864356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.
    Antoniou T; Men S; Tadrous M; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109473. PubMed ID: 35523113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
    Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Kumar A; Linas BP; Morgan JR; Murphy SM; Walley AY; Yan S; Schackman BR; Marshall BDL
    Addiction; 2022 May; 117(5):1372-1381. PubMed ID: 34825427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
    Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
    J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis.
    Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T
    Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
    Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
    J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
    Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone Accessibility Under the State Standing Order Across Mississippi.
    Gravlee E; Ramachandran S; Cafer A; Holmes E; McGregor J; Jordan T; Rosenthal M
    JAMA Netw Open; 2023 Jul; 6(7):e2321939. PubMed ID: 37410464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019.
    Chatterjee A; Yan S; Lambert A; Morgan JR; Green TC; Jeng PJ; Jalali A; Xuan Z; Krieger M; Marshall BDL; Walley AY; Murphy SM
    Health Serv Res; 2023 Oct; 58(5):1141-1150. PubMed ID: 37408299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.
    Antoniou T; McCormack D; Campbell T; Sutradhar R; Tadrous M; Lum-Wilson N; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2020 Nov; 216():108238. PubMed ID: 32891910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
    Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
    Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.